Lifesaving liver disease medicines
Versantis develops a new generation of liver disease therapeutics and diagnostics.
We are committed to the translation of life-saving therapies for acute hepatic diseases, where the medical need is dramatically high.
A life-saving therapy
Versantis’ lead product candidate, VS-01, is the first treatment for acute-on-chronic liver failure (ACLF), a life-threatening condition of high unmet medical need. The mortality of ACLF patients is alarming due to multi-organ failures resulting in dangerous accumulations of toxins in the blood. The versatile mechanism of action of VS-01 can simultaneously support the affected organs (liver, kidneys, brain), encourage liver regeneration, and save patients’ lives.
Versantis in the Top10 of the best Swiss Biotech Startups.